Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 26 October 2026.

Announcements

405

Total raised

£13.4B

disclosed amounts

This month

£87.7M

raised so far

Series B
£27.0M

The financing will support the final development and commercial launch of the company multi-link antenna technology.

"We are delighted to announce this new funding today, which will bring our game-changing technology to reality within the next 12 months. The strong interest we have received from across the industry has given us the confidence to accelerate our growth plans and bring forward the commercialisation of our groundbreaking new terminals, harnessing the potential of the thousands of new satellites being launched across multiple orbits in the year ahead."
— John Finney, Founder and CEO
Series B
£25.3M

Scottish Equity Partners led the growth equity round to accelerate product development and international expansion.

"APIs are everywhere. Ordered a pizza online? You can thank APIs for that. Just applied for a credit card? That's APIs from start to finish. The modern enterprise is at its core an API company, and those that want to survive are expanding their API ecosystems rapidly. With that growth comes an increasing need to manage, monitor and secure that complexity."
— Martin Buhr, CEO and co-founder
Series B
£27.5M

The Series B round was led by Lakestar with backing from institutional investors and venture funds to support team growth and product expansion.

"accuRx’s product has reinvigorated communication with our patients, enabling a better relationship between GPs and patients, which has ultimately led to better care provision. Our patients now have the confidence that they’re getting speedy and accurate responses from our team, and the use of regular Florey questionnaires to gather more information from our patients has been transformative for clinical record keeping and the care we provide. We’re thrilled that accuRx has received funding which will enable it to expand its primary care product set, some of which we’re trialling at the moment. We’re also excited about accuRx’s progress into secondary care as better interaction between primary and secondary care is a huge step forward for safer and more effective patient care."
— David Triska, GP Partner